Rogier Rooswinkel PhD
General Partner
Granite Bio is a clinical stage company developing first-in-class therapeutic antibodies to selectively deplete and modulate pathogenic immune cells involved in inflammation and fibrosis initiation and progression.
Granite Bio is pursuing unique targets for inflammatory and fibrotic indications, with broad applicability. Based on the extensive preclinical data package, strong biologic rationale and high unmet need, first-in-human trials will be conducted in both inflammatory bowel disease and fibrotic indications.
The lead program is a first-in-class therapeutic antibody with a novel mode-of-action that resembles an "innate Rituximab" with the potential to improve on safety and effectivity.
Industry
Biotech
Status
Current
Location
Switzerland
Forbion team
Audrey Cacaly MSc
Principal